LOGIN  |  REGISTER
Viking Therapeutics

Palatin Technologies to Report Fourth Quarter and Fiscal Year End 2024 Results

September 26, 2024 | Last Trade: US$1.18 0.03 -2.48
  • Teleconference and Webcast to be held on October 1, 2024

CRANBURY, N.J., Sept. 26, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2024 operating results on Tuesday, October 1, 2024, before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on October 1, 2024 at 11:00 AM Eastern Time. The conference call will include a review of the company's operating results and an update on programs under development.

Schedule for the Operating Results Press Release, Conference Call / Audio Webcast

Q4 & Fiscal Year End 2024 Results Press Release                 

10/01/2024 at 7:30 a.m. ET

Q4 & Fiscal Year End 2024 Conference Call-Live               

10/01/2024 at 11:00 a.m. ET

   US Toll Free Dial-In Number:                                        

1-888-506-0062

   International Dial-In Number:                                        

1-973-528-0011

   Participant Access Code:                                                 

252326

  

Q4 & Fiscal Year End 2024 Conference Call-Replay              

10/01/2024-10/15/2024

   US Toll Free Dial-In Number:                                          

1-877-481-4010

   International Dial-In Number:                                         

1-919-882-2331

   Participant Access Code:                                              

51290

The audio webcast and replay can be accessed by logging on to the "Investors-Webcasts" section of Palatin's website at http://www.palatin.com or by clicking here.

About Palatin

Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page